124 related articles for article (PubMed ID: 30963174)
21. BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.
Hao L; ElShamy WM
Int J Cancer; 2007 Jul; 121(1):39-46. PubMed ID: 17278098
[TBL] [Abstract][Full Text] [Related]
22. Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin.
Li H; Sekine M; Tung N; Avraham HK
Mol Cancer Res; 2010 Mar; 8(3):407-20. PubMed ID: 20215423
[TBL] [Abstract][Full Text] [Related]
23. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
24. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q
Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231
[TBL] [Abstract][Full Text] [Related]
25. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
26. Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Vilasco M; Communal L; Hugon-Rodin J; Penault-Llorca F; Mourra N; Wu Z; Forgez P; Gompel A;
Breast Cancer Res Treat; 2013 Nov; 142(2):283-96. PubMed ID: 24166279
[TBL] [Abstract][Full Text] [Related]
27. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
28. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Kawai H; Li H; Chun P; Avraham S; Avraham HK
Oncogene; 2002 Oct; 21(50):7730-9. PubMed ID: 12400015
[TBL] [Abstract][Full Text] [Related]
29. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
Yeung BH; Kwan BW; He QY; Lee AS; Liu J; Wong AS
Oncogene; 2008 Dec; 27(53):6782-9. PubMed ID: 18776923
[TBL] [Abstract][Full Text] [Related]
30. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
31. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
32. Human Chorionic Gonadotropin and Breast Cancer.
Schüler-Toprak S; Treeck O; Ortmann O
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28754015
[TBL] [Abstract][Full Text] [Related]
33. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
34.
Poh W; Dilley RL; Moliterno AR; Maciejewski JP; Pratz KW; McDevitt MA; Herman JG
Clin Cancer Res; 2019 Apr; 25(8):2513-2522. PubMed ID: 30692098
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.
Bindra RS; Gibson SL; Meng A; Westermark U; Jasin M; Pierce AJ; Bristow RG; Classon MK; Glazer PM
Cancer Res; 2005 Dec; 65(24):11597-604. PubMed ID: 16357170
[TBL] [Abstract][Full Text] [Related]
36. FOXP3 regulates sensitivity of cancer cells to irradiation by transcriptional repression of BRCA1.
Li W; Katoh H; Wang L; Yu X; Du Z; Yan X; Zheng P; Liu Y
Cancer Res; 2013 Apr; 73(7):2170-80. PubMed ID: 23319807
[TBL] [Abstract][Full Text] [Related]
37. BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
Zhang B; Lyu J; Liu Y; Wu C; Yang EJ; Pardeshi L; Tan K; Wong KH; Chen Q; Xu X; Deng CX; Shim JS
Oncogene; 2018 Dec; 37(49):6341-6356. PubMed ID: 30042414
[TBL] [Abstract][Full Text] [Related]
38. Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis.
Lo PK; Zhang Y; Wolfson B; Gernapudi R; Yao Y; Duru N; Zhou Q
Oncotarget; 2016 Oct; 7(40):65067-65089. PubMed ID: 27556296
[TBL] [Abstract][Full Text] [Related]
39. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.
Tassone P; Di Martino MT; Ventura M; Pietragalla A; Cucinotto I; Calimeri T; Bulotta A; Neri P; Caraglia M; Tagliaferri P
Cancer Biol Ther; 2009 Apr; 8(7):648-53. PubMed ID: 19333003
[TBL] [Abstract][Full Text] [Related]
40. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer.
Kosinsky RL; Helms M; Zerche M; Wohn L; Dyas A; Prokakis E; Kazerouni ZB; Bedi U; Wegwitz F; Johnsen SA
Cell Death Dis; 2019 Dec; 10(12):911. PubMed ID: 31801945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
